WW
Ww International, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$1.8M | Q1 2026 | — |
|
|
|||
| Adjusted Gross Margin non-GAAP | 73.6% | Q1 2026 | — |
| End of Period Clinical Subscribers | 197K | Q1 2026 | — |
| Total End of Period Subscribers | 2.7M | Q1 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 11.1% | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WW
this stock
Ww International, Inc.
|
$153.98M | -47.3% | +12.2% | — | 19.4% |
|
HCA
HCA Healthcare, Inc.
|
$90.20B | -12.8% | +7.1% | 14.0 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$27.44B | -15.0% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$17.59B | +2.8% | -2.3% | 10.6 | 4.3% |
|
DVA
Davita Inc.
|
$14.95B | +104.9% | +6.5% | 21.7 | 7.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WW | -5.6% | -16.6% | -35.1% | -3.6% | -47.3% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -7.0% | -20.7% | -44.1% | -4.7% | -58.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.